Abivax’s stock swung after the company’s positive phase 3 ABTECT maintenance trial topline results were tempered by safety concerns flagged by analysts. The study assessed obefazimod in moderately to severely active ulcerative colitis (NCT05535946), with investors reacting to malignancy cases observed within the trial dataset. Analysts at Jefferies, Morgan Stanley, Truist, and Wedbush highlighted the concern after malignancies were reported among nine patients out of 580 enrolled. Jefferies downgraded Abivax from Buy to Hold and cut its 12-month price target, explicitly citing the cancer signal as an overhang on investor interest, strategic optionality, and uptake. Even with sell-side disagreement on magnitude, the immediate market reaction shows how malignancy signals in late-stage maintenance can rapidly alter perceived probability of commercial success and potential labeling implications.